Results 171 to 180 of about 13,526 (188)

Nintedanib alleviates pulmonary fibrosis in vitro and in vivo by inhibiting the FAK/ERK/S100A4 signalling pathway

International Immunopharmacology, 2022
Wenting Yang, Menglin Zhang, Honglan Zhu
exaly  

The influence of green tea extract on nintedanib’s bioavailability in patients with pulmonary fibrosis

Biomedicine and Pharmacotherapy, 2022
Mathijssen Ron, Stijn Koolen, Marlies Wijsenbeek   +2 more
exaly  

Nintedanib

2015
Wörmann, Bernhard, Thomas, Michael, Wolf, Jürgen, Reinmuth, Niels, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss   +5 more
openaire   +1 more source

Nintedanib

Reactions Weekly, 2018
openaire   +2 more sources

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

Annals of Oncology, 2018
Eric Van Cutsem, Sara Lonardi, H J Lenz
exaly  

Novel Mechanisms for the Antifibrotic Action of Nintedanib.

American Journal of Respiratory Cell and Molecular Biology, 2016
Deepali Kurundkar, Sunad Rangarajan, Yan Y Sanders   +2 more
exaly  

Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions

Respirology, 2017
Huaqing Zhao, Gerard J Criner, Jonathan A Galli   +2 more
exaly  

Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer

Cancer Letters, 2015
Margaret A Schwarz, Niranjan Awasthi, Roderich E Schwarz   +2 more
exaly  

Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity

Journal of Hepatology, 2014
Chun-Wei Chang, Kuen-Feng Chen, Hui-Chuan Yu   +2 more
exaly  

Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship

Pulmonary Pharmacology and Therapeutics, 2020
Megan Vierhout, Kjetil Ask, David Shitrit   +2 more
exaly